Schistosomiasis, also known as bilharzia or snail fever, is a neglected tropical disease caused by parasitic schistosomes (also known as blood flukes) indigenous to tropical and subtropical regions of the developing world.^[@ref1]−[@ref4]^*Biomphalaria* freshwater snails serve as intermediate hosts for *Schistosoma mansoni* and release infectious larvae (cercariae), which burrow into human skin upon contact with contaminated water sources. After definitive host penetration, the parasite transforms into a schistosomulum that enters the circulation and migrates to the hepatic portal and mesenteric veins surrounding the liver. Here, schistosomula develop into sexually mature adults (male and female forms) that can evade immunity and thrive for many years.^[@ref5]−[@ref7]^ Intravascular adult females produce hundreds of eggs daily during this time, which either cross the intestinal lumen to continue the lifecycle or circulate to the liver where they induce a robust host immunological response.^[@ref5]^ Chronic inflammation of the liver ultimately results, leading to portal vein hypertension and severe hepatic fibrosis. Although schistosomiasis is usually treated effectively with praziquantel, currently believed to target schistosomal voltage-gated Ca^2+^ channels,^[@ref8]^ the continuous threat of praziquantel-resistant schistosomes portends an urgent need for alternative drug targets.^[@ref9]−[@ref12]^

The binuclear manganese metalloenzyme arginase may comprise just such an alternative. Although arginase activity was first discovered in *S. mansoni* 50 years ago^[@ref13]^ and implicated in [l]{.smallcaps}-proline biosynthesis,^[@ref14]^*S. mansoni* arginase (SmARG) was not enzymatically characterized until recently.^[@ref15]^ The full-length mRNA for SmARG encodes a 364-residue protein with an amino acid sequence that is 42 and 40% identical with those of human arginases I and II, respectively, which catalyze the hydrolysis of [l]{.smallcaps}-arginine to yield [l]{.smallcaps}-ornithine and urea (Figure [1](#fig1){ref-type="fig"}a).^[@ref16],[@ref17]^ All residues important for catalysis by the human isozymes, including two histidine and four aspartate ligands to the binuclear manganese cluster, are strictly conserved in SmARG. Interestingly, SmARG exhibits a relatively high turnover number of 537 s^--1^, approximately 2-fold higher than that measured for human arginase II and 20% higher than that reported for human arginase I.^[@ref18],[@ref19]^ Using a homology model of SmARG based on the crystal structure of human arginase I,^[@ref16]^ Fitzpatrick and colleagues predicted the formation of a disulfide linkage between proximal residues C291 and C332 in the active site; the enzyme activity is significantly reduced in the presence of reducing agents, consistent with the potential functional relevance of a disulfide linkage.^[@ref15]^

![(a) Reaction catalyzed by arginase. (b) Arginase inhibitors 2(*S*)-amino-6-boronohexanoic acid (ABH), *S*-(boronoethyl)-[l]{.smallcaps}-cysteine (BEC), *N*-hydroxy-[l]{.smallcaps}-arginine (NOHA), nor-*N*-hydroxy-[l]{.smallcaps}-arginine (nor-NOHA), (*R*)-2-amino-6-borono-2-\[2-(piperidin-1-yl)ethyl\]hexanoic acid (ABH~PE~), and (*R*)-2-amino-6-borono-2-\[1-(3,4-dichlorobenzyl)piperidin-4-yl\]hexanoic acid (ABH~DP~). Although ABH~DP~ is shown as the single stereoisomer that binds to SmARG, the racemic mixture was utilized for the experiments described herein.](bi-2014-004519_0010){#fig1}

SmARG is expressed in all life stages of the parasite that interact with the human host^[@ref15]^ and is hypothesized to play a role in immune evasion. By depleting the [l]{.smallcaps}-arginine substrate otherwise utilized for nitric oxide (NO) biosynthesis, SmARG can attenuate the anti-schistosomula NO-mediated immune response of classically activated macrophages.^[@ref20]^ A similar strategy of arginase-facilitated immune evasion is exploited by *Leishmania* parasites in leishmaniasis,^[@ref21]−[@ref23]^*Helicobacter pylori* in peptic ulcer disease,^[@ref24],[@ref25]^ and certain cancer tumor cells.^[@ref26]−[@ref29]^ Accordingly, inhibition of SmARG might render the parasite more susceptible to the immune response. If so, then SmARG may comprise a new target for structure-based drug design in the treatment of schistosomiasis.^[@ref15]^

As the first step in exploring the "druggability" of SmARG, we now report the X-ray crystal structures of the unliganded enzyme and its complexes with selected inhibitors (Figure [1](#fig1){ref-type="fig"}b), including the classical boronic acid amino acid inhibitors 2(*S*)-amino-6-boronohexanoic acid (ABH)^[@ref30]^ and *S*-(boronoethyl)-[l]{.smallcaps}-cysteine (BEC).^[@ref31]^ Additionally, we report crystal structures of SmARG complexes with the *N*-hydroxyguanidinium amino acids *N*-hydroxy-[l]{.smallcaps}-arginine (NOHA)^[@ref32]^ and nor-*N*-hydroxy-[l]{.smallcaps}-arginine (nor-NOHA),^[@ref33]^ as well as the simple amino acids [l]{.smallcaps}-ornithine (the catalytic product), [l]{.smallcaps}-lysine, and [l]{.smallcaps}-valine. Finally, to advance beyond classical amino acid inhibitor designs, we report the crystal structures of SmARG complexed with two novel α,α-disubstituted amino acid derivatives of ABH: (*R*)-2-amino-6-borono-2-\[2-(piperidin-1-yl)ethyl\]hexanoic acid (ABH~PE~)^[@ref34]^ and (*R*)-2-amino-6-borono-2-\[1-(3,4-dichlorobenzyl)piperidin-4-yl\]hexanoic acid (ABH~DP~).^[@ref35]^ The additional α-substituents of ABH~PE~ and ABH~DP~ make new interactions that enhance enzyme--inhibitor affinity. These studies illuminate structure--function relationships relevant to the understanding of catalysis by SmARG and provide a foundation for exploring the design of next-generation inhibitors targeting a distinctive new region of the protein surface.

Materials and Methods {#sec2}
=====================

Materials {#sec2.1}
---------

Manganese(II) chloride tetrahydrate (≥99%), [l]{.smallcaps}-arginine, and α-isonitrosopropiophenone were purchased from Sigma. Tris(2-carboxyethyl)phosphine hydrochloride (98%, TCEP) was purchased from Gold Biotechnology. ABH was purchased from Enzo Life Sciences (Farmingdale, NY). NOHA, nor-NOHA, and BEC were purchased from Cayman Chemical Co. (Ann Arbor, MI). ABH~PE~ and ABH~DP~ were the generous gifts of New England Discovery Partners. A 30% (w/v) PEG 20000 solution, a 50% (w/v) PEG 3350 solution, a 50% (w/v) PEG 10000 solution, and a 100% Tacsimate (pH 7.0) solution were purchased from Hampton Research. All other chemicals were purchased from Fisher Scientific.

Expression and Purification of SmARG {#sec2.2}
------------------------------------

A silent mutation was introduced into the gene encoding wild-type SmARG prepared in a TOPO vector to eliminate a native NdeI site by using the QuickChange method (Stratagene) with the following oligonucleotide primers \[sense, 5′-GGT AAT ATG AGT CGG GCG GCA [CAC]{.ul} ATG CAG CAG ACA AAA CAA TAA TCG-3′; antisense, 5′-CGA TTA TTG TTT TGT CTG CAT [GTG]{.ul} TGC CGC CCG ACT CAT AAT ACC-3′ (underlined bases indicate the silent mutation)\]. The coding sequence for SmARG was then amplified by polymerase chain reaction (PCR) using oligonucleotide primers \[sense, 5′-GCA GCA [CATATG]{.ul} ATG TTG AAA TCA GTC GCG ACC-3′; antisense, 5′-GCA GCA [CTCGAG]{.ul} TTA TTG TTT TGT CTG CAT GTG TGC-3′ (underlined bases represent the restriction enzyme recognition sites)\]. The PCR product was subcloned into NdeI and XhoI sites of the pET-28a vector (Novagen Inc.), yielding an N-terminal hexahistidine tag, a thrombin cleavage site, and a linker (MGSSHHHHHHSSGLVPRGSHM). All DNA constructs were verified by DNA sequencing at the Perelman School of Medicine of the University of Pennsylvania.

SmARG was overexpressed in *Escherichia coli* BL21(DE3) cells. Transformed cell cultures were grown in Lysogeny-Broth (LB) medium supplemented with 50 μg/L kanamycin. Expression was induced by 1 mM isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG) (Carbosynth) for 16 h at 20 °C when the OD~600~ reached 0.6--0.7. Cells were harvested by centrifugation at 6000*g* for 10 min. The cell pellet was resuspended in buffer A \[50 mM K~2~HPO~4~ (pH 8.0), 300 mM NaCl, 10% (v/v) glycerol, and 1 mM TCEP\]. Cells were lysed by sonication on ice using a Sonifer 450 (Branson), and the cell lysate was clarified by centrifugation at 26895*g* for 1 h. Proteins were isolated from lysate by affinity chromatography with a Talon column (Clontech Laboratories, Mountain View, CA). After being washed with 10 column volumes of 20 mM imidazole in buffer A, SmARG was eluted with a 200 mL gradient from 20 to 300 mM imidazole. Pooled fractions were concentrated and applied to a Superdex 200 preparative grade 26/60 size exclusion column (GE Healthcare) with buffer B \[50 mM bicine (pH 8.5) and 100 μM MnCl~2~\]. The estimated purity of SmARG was \>95% on the basis of sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Although the N-terminal hexahistidine tag and linker segment contained a thrombin cleavage site, the recombinant enzyme was not treated with thrombin and hence contained a full-length N-terminus. The enzyme was concentrated to 40 mg/mL, flash-frozen with liquid nitrogen, and stored at −80 °C.

The C291A and C332A mutants of SmARG were prepared by PCR mutagenesis with the following primers (underlined bases indicate mutated codons): C291A, 5′-GAA GGT TTG AGA ATA [GCT]{.ul} GAA GAA GTT TC-3′ (sense) and 5′-GAA ACT TCT TC[AGC]{.ul}T ATT CTC AAA CCT TC-3′ (antisense); C332A, 5′-CAT ATT TTA AGA GCA [GCT]{.ul} TTA GGC CAT TGT CG-3′ (sense) and 5′-CGA CAA TGG CCT AA[AGC]{.ul}T GCT CTT AAA ATA TG-3′ (antisense). Each mutant was purified as described above for the wild-type enzyme.

Activity Assays {#sec2.3}
---------------

Arginase activity was assayed by a colorimetric assay developed by Archibald with slight modifications.^[@ref36]^ Briefly, 0.5--50 mM [l]{.smallcaps}-arginine (pH 8.5) was added to a solution of 50 mM 4-(2-hydroxyethyl)piperazine-1-propanesulfonic acid (EPPS) (pH 8.5) and 100 μM MnCl~2~, and the reaction was initiated by adding 1 μM SmARG in a total volume of 200 μL at 21 °C. The reaction was terminated after 1 min using 30 μL of a 3:1 (v/v) concentrated acid/dye solution {H~2~SO~4~/H~3~PO~4~/H~2~O \[1:3:1 (v/v/v)\] mixture with 245 mM α-isonitrosopropiophenone in ethanol}. Samples were heated to 90 °C for 1 h in a thermocycler to ensure complete reaction of urea with the dye. To quantify urea formation, the absorbance of each sample was assessed at a λ of 550 nm using a Tecan Infinite M1000 Pro Microplate Reader. Kinetic parameters were determined with Graphpad Prism (2008). The *K*~i~ values for ABH and NOHA were calculated using the modified Michaelis--Menten equation for competitive inhibition. All measurements were performed in triplicate.

Isothermal Titration Calorimetry (ITC) {#sec2.4}
--------------------------------------

A MicroCal iTC~200~ calorimeter (GE Healthcare) was used to measure the dissociation constants of SmARG--inhibitor complexes using previously reported procedures.^[@ref16],[@ref31]^ Briefly, SmARG was exhaustively dialyzed against 50 mM Bicine (pH 8.5), 100 μM MnCl~2~, and 1.0 mM TCEP \[5% (v/v) DMSO was included in the dialysis buffer when SmARG was titrated with ABH~PE~ and ABH~DP~\]. The inhibitor (ABH, 0.547 mM; NOHA, 1.097 mM; nor-NOHA, 0.443 mM; ABH~PE~, 0.410 mM; ABH~DP~, 0.436 mM) was dissolved in dialysis buffer. The inhibitor was titrated into the sample cell (0.2 mL) overfilled with SmARG (typically 20--40 μM) with sequential injections. An initial 0.2 μL injection was not used in the data analysis. Data analysis was performed using Origin version 7.0. For SmARG complexes with nor-NOHA, ABH, ABH~PE~, and ABH~DP~, data were best fit assuming a single binding site. For the SmARG--NOHA complex, data were best fit with the equation describing two sets of independent sites, i.e., a model in which binding to one site (association constant *K*~1~) has a higher affinity than binding to the second site (association constant *K*~2~):where *Q* is the heat evolved during the course of the reaction, \[E\]~t~ is the total enzyme concentration, *V* is the cell volume, *n*~1~ is the number of inhibitor equivalents required to saturate the first binding site, *n*~2~ is the number of equivalents to saturate the second site, Δ*H*~1~ and Δ*H*~2~ are the enthalpies per mole of ligand of binding to the first and second sites, respectively, and \[L\] is the inhibitor concentration. Note that dissociation constants *K*~d1~ = 1/*K*~1~ and *K*~d2~ = 1/*K*~2~.

Crystallography {#sec2.5}
---------------

Unliganded SmARG crystals were prepared by the sitting drop vapor diffusion method at 4 °C. Typically, a 4 μL drop of a protein solution \[10 mg/mL SmARG, 50 mM bicine (pH 8.5), and 100 μM MnCl~2~\] was mixed with a 4 μL drop of a precipitant solution \[12% (w/v) PEG 20000 and 0.1 M imidazole (pH 7.0)\] and equilibrated against a 500 μL reservoir of a precipitant solution. Cubic crystals first appeared after 2 days and grew to maximal size in 3 days. To obtain crystals of the SmARG--[l]{.smallcaps}-ornithine, SmARG--[l]{.smallcaps}-valine, and SmARG--[l]{.smallcaps}-lysine complexes, unliganded SmARG crystals were soaked with each ligand (50 mM) in a 20 μL drop of a soaking solution \[14% PEG 20000 and 0.1 M imidazole (pH 7.0)\] equilibrated against a 500 μL reservoir of a soaking solution for 24 h. To cocrystallize SmARG with the higher-affinity arginase inhibitors ABH, BEC, NOHA, and nor-NOHA, as well as the α,α-disubstituted amino acid inhibitors ABH~PE~ and ABH~DP~, SmARG was incubated with each inhibitor (10 mM) on ice for 1 h before the crystallization experiment. Typically, a 1 μL drop of protein solution (9 mg/mL SmARG, 45 mM bicine, 90 μM MnCl~2~, and 10 mM inhibitor) was added to a 1 μL drop of a precipitant solution \[4% (v/v) Tacsimate (pH 7.0) and 12% (w/v) PEG 3350 for SmARG--ABH and SmARG--BEC complexes; 0.2 M potassium sodium tartrate tetrahydrate, 0.1 M Bis-Tris (pH 6.5), and 10% (w/v) PEG 10000 for the SmARG--NOHA complex; 0.2 M [l]{.smallcaps}-proline, 0.1 M HEPES (pH 7.5), and 10% (w/v) PEG 3350 for the SmARG--norNOHA complex; 0.1 M HEPES (pH 7.4) and 12% (w/v) PEG 3350 for the SmARG--ABH~PE~ complex; and 0.15 M CsCl and 13% (w/v) PEG 3350 for the SmARG--ABH~DP~ complex\] and equilibrated against a 100 μL reservoir of a precipitant solution. Cubic crystals appeared overnight and grew to maximal size in 3 days. All crystals were flash-cooled in liquid nitrogen after being transferred to a cryoprotectant solution consisting of mother liquor supplemented with 15--20% (v/v) glycerol.

X-ray diffraction data were collected on beamline X29 at the National Synchrotron Light Source (NSLS, Brookhaven National Laboratory, Upton, NY). Diffraction data were integrated and scaled with HKL2000.^[@ref37]^ Data collection and reduction statistics are listed in Table [1](#tbl1){ref-type="other"}. All crystals belonged to space group *P*2~1~3 with four molecules in the asymmetric unit, each belonging to a separate SmARG trimer in the unit cell. The structure of unliganded SmARG was determined by molecular replacement using PHASER^[@ref38]^ as implemented in the CCP4 suite of programs^[@ref39]^ with the atomic coordinates of unliganded human arginase I (PDB entry 2ZAV)^[@ref40]^ utilized as a search probe for rotation and translation function calculations. Iterative cycles of refinement and model building were performed using PHENIX and COOT, respectively.^[@ref41],[@ref42]^ The structures of SmARG--inhibitor complexes were determined thereafter by molecular replacement using the atomic coordinates of unliganded SmARG as a search probe. Solvent molecules and inhibitors were added in the final stages of refinement for each structure. The quality of each final model was verified with PROCHECK, and the secondary structure was defined with DSSP.^[@ref43],[@ref44]^ Disordered segments excluded from the final models include the N-terminal hexahistidine tag and its linker segment, residues M1--P17, surface loop K111--S119, and T362--Q364 at the C-terminus. Refinement statistics are listed in Table [1](#tbl1){ref-type="other"}. Protein structure figures were prepared with PyMol (<http://www.pymol.org>) and PhotoshopCS.

###### Data Collection and Refinement Statistics of SmARG Complexes

                                                            unliganded              ABH                     ABH~PE~                 ABH~DP~                 nor-NOHA                NOHA                    BEC                     [l]{.smallcaps}-ornithine   [l]{.smallcaps}-valine   [l]{.smallcaps}-lysine
  --------------------------------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- --------------------------- ------------------------ ------------------------
  PDB entry                                                 4Q3P                    4Q3Q                    4Q3S                    4Q3R                    4Q3U                    4Q3T                    4Q3V                    4Q42                        4Q40                     4Q41
  Data Collection                                                                                                                                                                                                                                                                        
  space group                                               *P*2~1~3                *P*2~1~3                *P*2~1~3                *P*2~1~3                *P*2~1~3                *P*2~1~3                *P*2~1~3                *P*2~1~3                    *P*2~1~3                 *P*2~1~3
  resolution (Å)                                            2.50                    2.00                    2.11                    2.17                    2.50                    2.14                    2.70                    2.05                        1.83                     2.20
  no. of reflections measured (total/unique)                468739/65315            1358593/126488          993349/106363           1704963/96325           382879/61714            599891/102397           198632/51489            1458071/118020              813401/163491            659561/94329
  unit cell parameters \[*a* = *b* = *c* (Å)\]              178.4                   178.2                   178.2                   177.5                   178.3                   177.8                   178.4                   178.4                       177.8                    177.4
  completeness[a](#t1fn1){ref-type="table-fn"} (%)          99.9 (99.6)             100 (99.9)              98.5 (96.1)             98.3 (92.5)             94.4 (87.0)             99.9 (99.6)             98.8 (99.7)             100 (100)                   99.9 (99.9)              100 (100)
  *I*/σ~*I*~[a](#t1fn1){ref-type="table-fn"}                13.7 (2.1)              13.5 (3.1)              14.7 (2.0)              16.5 (2.0)              18.2 (2.1)              12.0 (2.0)              10.5 (2.0)              19.2 (3.8)                  14.1 (2.1)               13.5 (3.5)
  *R*~sym~[b](#t1fn2){ref-type="table-fn"}                  0.167 (0.834)           0.153 (0.831)           0.106 (0.757)           0.165 (1.190)           0.118 (0.712)           0.150 (0.883)           0.158 (0.655)           0.130 (0.790)               0.099 (0.813)            0.123 (0.667)
  *R*~pim~[c](#t1fn3){ref-type="table-fn"}                  0.066 (0.350)           0.045 (0.262)           0.031 (0.342)           0.041 (0.376)           0.047 (0.412)           0.066 (0.420)           0.088 (0.353)           0.079 (0.175)               0.044 (0.363)            0.037 (0.222)
  redundancy                                                7.2 (6.4)               10.7 (9.8)              9.3 (5.3)               17.7 (10.1)             6.3(3.6)                5.9 (5.2)               3.9 (3.6)               12.4 (12.4)                 5.0 (5.0)                7.0 (7.0)
  Refinement                                                                                                                                                                                                                                                                             
  no. of reflections (refinement/test set)                  65276/3303              118487/5927             106337/5301             96490/4812              61299/3100              102353/5117             51451/2636              111704/5586                 152572/7678              91351/4574
  *R*~work~/*R*~free~ (%)[d](#t1fn4){ref-type="table-fn"}   17.7/21.4 (24.7/30.4)   16.8/20.2 (20.1/24.5)   17.3/20.6 (23.2/25.8)   17.4/20.6 (24.9/29.4)   17.4/22.5 (21.7/29.0)   17.6/20.9 (24.8/29.2)   16.7/21.7 (24.1/31.2)   17.4/20.8 (20.4/23.5)       17.4/19.5 (25.5/26.5)    17.2/20.1 (23.5/26.1)
  no. of protein atoms[e](#t1fn5){ref-type="table-fn"}      10271                   10241                   10270                   10120                   10182                   10243                   10306                   10289                       10261                    10223
  no. of solvent atoms                                      495                     895                     849                     627                     390                     607                     353                     679                         1019                     397
  no. of ligand atoms                                       36                      88                      132                     173                     84                      127                     75                      72                          109                      56
  no. of Mn^2+^ ions                                        8                       8                       8                       8                       8                       8                       8                       8                           8                        8
  rmsd                                                                                                                                                                                                                                                                                    
  bonds (Å)                                                 0.005                   0.010                   0.006                   0.009                   0.009                   0.006                   0.005                   0.008                       0.009                    0.009
  angles (deg)                                              0.9                     1.2                     1.0                     1.1                     1.2                     1.0                     0.9                     1.1                         1.1                      1.1
  average *B* factor (Å^2^)                                                                                                                                                                                                                                                               
  main chain                                                36                      30                      30                      32                      44                      29                      30                      32                          27                       47
  side chain                                                37                      34                      33                      34                      45                      32                      32                      36                          31                       50
  solvent                                                   29                      34                      33                      30                      38                      30                      24                      35                          33                       43
  Mn^2+^ ions                                               29                      21                      23                      24                      37                      24                      25                      26                          20                       37
  ligands                                                   37                      34                      34                      45                      43                      42                      32                      40                          32                       52
  Ramachandran plot (%)                                                                                                                                                                                                                                                                   
  allowed                                                   91.4                    92.0                    92.2                    91.4                    90.5                    92.0                    91.4                    92.1                        91.5                     92.0
  additionally allowed                                      8.6                     8.0                     7.8                     8.6                     9.5                     8.0                     8.6                     7.9                         8.5                      8.0
  generously allowed                                        0.0                     0.0                     0.0                     0.0                     0.0                     0.0                     0.0                     0.1                         0.0                      0.0
  disallowed                                                0.0                     0.0                     0.0                     0.0                     0.0                     0.0                     0.0                     0.0                         0.0                      0.0

Values in parentheses refer to data for the highest-resolution shell.

*R*~sym~ = ∑~*h*~∑~*i*~\|*I*(*h*)~*i*~ -- ⟨*I*(*h*)⟩\|/∑~*h*~∑~*i*~*I*(*h*)~*i*~, where *I*(*h*) is the intensity of reflection *h*, ∑~*h*~ is the sum over all reflections, and ∑~*i*~ is the sum over *i* measurements of reflection *h*.

*R*~pim~ = ∑(1/*n* -- 1)^1/2^\|*I* -- ⟨*I*⟩\|/∑*I*, where *n* is the number of observations (redundancy) and ⟨*I*⟩ is the average intensity calculated from replicate data.

*R*~work~ = ∑\|\|*F*~o~\| -- \|*F*~c~\|\|/∑\|*F*~o~\| for reflections contained in the working set. *R*~free~ = ∑\|\|*F*~o~\| -- \|*F*~c~\|\|/∑\|*F*~o~\| for reflections contained in the test set held aside during refinement. \|*F*~o~\| and \|*F*~c~\| are the observed and calculated structure factor amplitudes, respectively.

Per asymmetric unit.

SmARG Transcription Profile {#sec2.6}
---------------------------

Data from the 37632-element *S. mansoni* long-oligonucleotide DNA microarray studies of Fitzpatrick and colleagues^[@ref45]^ were interrogated to find the expression profile of SmARG across 14 different life cycle stages. Raw and normalized fluorescence intensity values are available via Array Express under experimental accession number E-MEXP-2094.

Helminth Fluorescence Bioassay {#sec2.7}
------------------------------

Mechanically transformed *S. mansoni* schistosomula were treated with the arginase inhibitors ABH (Enzo Life Sciences), NOHA (Sigma), and nor-NOHA (Enzo Life Sciences) at a final concentration of 100 μM and incubated for 24 h at 37 °C in a humidified environment containing 5% CO~2~. The viability of *S. mansoni* schistosomula subsequent to treatment was determined using the helminth fluorescence bioassay as previously described.^[@ref46]^ All assays were performed in duplicate.

Results {#sec3}
=======

SmARG Transcription Profile {#sec3.1}
---------------------------

The transcription profile of SmARG across 14 different *S. mansoni* life cycle stages (Figure [2](#fig2){ref-type="fig"}) confirms previously published semiquantitative reverse transcription PCR data showing that SmARG is maximally expressed in all life stages that interact with the definitive mammalian host but minimally expressed in life stages that interact with the intermediate snail host.^[@ref45]^ Thus, the upregulation of SmARG is specific to human infection by *S. mansoni*. If SmARG plays an important role during human infection, it could serve as a new target for the treatment of schistosomal infections.

![Expression profile of SmARG across 14 different life cycle stages of *S. mansoni* shown following interrogation of the 37632-element DNA microarray. Raw and normalized fluorescence intensity values are available via Array Express under experimental accession number E-MEXP-2094. Histograms represent the normalized mean fluorescence intensity ± the standard deviation of the mean.](bi-2014-004519_0001){#fig2}

Activity Assays and ITC Measurements {#sec3.2}
------------------------------------

Our measurements show that wild-type SmARG exhibits a turnover number (*k*~cat~) of 330 ± 60 s^--1^ and a *K*~M~ value of 12 ± 5 mM at pH 8.5 using Archibald's colorimetric assay^[@ref36]^ to quantify urea production in steady-state kinetic assays (Table [2](#tbl2){ref-type="other"}). These values are in reasonable agreement with previously reported values of 537 s^--1^ and 17 mM, respectively, for a slightly different SmARG construct at pH 9.7 containing the remnant of an N-terminal glutathione *S*-transferase fusion tag^[@ref15]^ instead of the hexahistidine tag and linker utilized herein. These values are also comparable to those measured for human arginase I, although the *K*~M~ values of SmARG are slightly larger (4--6-fold) than the *K*~M~ value reported for the human enzyme (Table [2](#tbl2){ref-type="other"}).

###### Enzyme Kinetics and Inhibitor Binding Affinities

                                                    *K*~M~ (mM)                             *k*~cat~ (s^--1^)                           *k*~cat~/*K*~M~ (M^--1^ s^--1^)                    *K*~i~ (ABH) (μM)                     *K*~d~ (ABH) (μM)                       *K*~i~ (NOHA) (μM)   *K*~d~ (NOHA) (μM)                    *K*~d~ (nor-NOHA) (μM)                  *K*~d~ (ABH~PE~) (μM)   *K*~d~ (ABH~DP~) (μM)
  ------------------------------------------------- --------------------------------------- ------------------------------------------- -------------------------------------------------- ------------------------------------- --------------------------------------- -------------------- ------------------------------------- --------------------------------------- ----------------------- -----------------------
  wild-type SmARG[a](#t2fn1){ref-type="table-fn"}   12 ± 5                                  330 ± 60                                    (3.0 ± 0.9) × 10^4^                                1.8 ± 0.6                             1.3 ± 0.2                               3.7 ± 0.8            0.33 ± 0.09, 13 ± 4                   0.36 ± 0.08                             0.26 ± 0.02             0.54 ± 0.08
  C291A SmARG[a](#t2fn1){ref-type="table-fn"}       90 ± 10                                 110 ± 10                                    (1.2 ± 0.3) × 10^3^                                nd                                    nd                                      nd                   nd                                    nd                                      nd                      nd
  C332A SmARG[a](#t2fn1){ref-type="table-fn"}       32 ± 9                                  100 ± 20                                    (3.3 ± 0.6) × 10^3^                                nd                                    nd                                      nd                   nd                                    nd                                      nd                      nd
  SmARG[b](#t2fn2){ref-type="table-fn"}             17                                      537                                         3.2 × 10^4^                                        nd                                    nd                                      nd                   nd                                    nd                                      nd                      nd
  human arginase I                                  3 ± 1[c](#t2fn3){ref-type="table-fn"}   340 ± 160[c](#t2fn3){ref-type="table-fn"}   (11 ± 2) × 10^4^[c](#t2fn3){ref-type="table-fn"}   3.5[d](#t2fn4){ref-type="table-fn"}   0.005[e](#t2fn5){ref-type="table-fn"}   nd                   3.6[f](#t2fn6){ref-type="table-fn"}   0.517[g](#t2fn7){ref-type="table-fn"}   nd                      nd

This study; determined by an enzyme assay at pH 8.5.

From ref ([@ref15]); determined by an enzyme assay at pH 9.7.

From ref ([@ref63]); determined by an enzyme assay at pH 8.5.

From ref ([@ref64]); determined by an enzyme assay at pH 9.5.

From ref ([@ref16]); *K*~d~ determined at pH 8.5 by isothermal titration calorimetry.

From ref ([@ref47]); *K*~d~ determined at pH 8.5 by surface plasmon resonance.

From ref ([@ref47]); *K*~d~ determined at pH 8.5 by surface plasmon resonance; however, isothermal titration calorimetry yielded a *K*~d~ of ∼50 nM.

Steady-state kinetic analysis yields an inhibition constant (*K*~i~) of 1.8 ± 0.6 μM for the SmARG--ABH complex, which is consistent with the ITC measurement of 1.3 ± 0.2 μM for the dissociation constant (*K*~d~) of this complex (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"}). Interestingly, ITC measurements indicate 260-fold tighter binding of ABH to human arginase I, but the inhibitory potencies of ABH against SmARG and human arginase I are comparable (Table [2](#tbl2){ref-type="other"}). The origin of the difference between *K*~i~ and *K*~d~ values is unknown.

ITC measurements indicate that *K*~d~ = 0.36 ± 0.08 μM for the SmARG--nor-NOHA complex (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"}). The binding of NOHA is slightly more complex, and ITC data are best fit by a model in which the binding affinity for the first site is higher (*K*~d~ = 0.33 ± 0.09 μM) than the binding affinity for the second site (*K*~d~ = 13 ± 4 μM). The location of the weaker binding site is unknown, because only the higher-affinity binding site is occupied in the crystal structure of the SmARG--NOHA complex (*vide infra*). Taken together, these data suggest that the *N*-hydroxyguanidinium moiety of nor-NOHA is ∼4-fold more effective as an inhibitor functional group targeting metal ion coordination than the tetrahedral boronate anion of ABH in binding to SmARG. This contrasts with human arginase I, which is preferentially inhibited (at least 10-fold) by ABH compared with nor-NOHA.^[@ref16],[@ref47]^ Possibly, these selectivity differences (summarized in Table [2](#tbl2){ref-type="other"}) could be exploited in developing inhibitors that preferentially block the parasitic enzyme.

Finally, ITC measurements indicate *K*~d~ values of 0.26 ± 0.02 and 0.54 ± 0.08 μM for SmARG--ABH~PE~ and −ABH~DP~ complexes, respectively (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"}). Notably, the additional α-substituent of these α,α-disubstituted amino acid inhibitors provides 2--5-fold enhancement of the affinity compared with that of the parent SmARG--ABH complex.

Structure of Unliganded SmARG {#sec3.3}
-----------------------------

The overall fold of the SmARG monomer is generally similar to that of unliganded human aginase I (PDB entry 2ZAV)^[@ref40]^ with an rmsd of 1.1 Å for 271 Cα atoms, which is consistent with the modest amino acid sequence identity of 42% between SmARG and human arginase I. SmARG oligomerizes to form a homotrimer (Figure [3](#fig3){ref-type="fig"}a) with a total buried surface area of 10980 Å^2^ (31% of the total solvent-accessible surface area) as determined by PISA.^[@ref48]^ As indicated by the sequence alignment with human arginase I, SmARG contains a 20-residue extension at the N-terminus and a 13-residue extension at the C-terminus, and a 12-residue insertion in the loop connecting α-helix B and β-strand 3.^[@ref15]^ The N-terminal extension (17 residues with the hexahistidine tag and its linker segment) and the inserted loop lack clearly defined electron density and are presumed to be disordered. Most of the C-terminal extension is fully ordered and contains two additional short α-helices previously unobserved in the crystal structures of arginases from other species. The S-shaped C-terminus is suggested to be important for oligomerization and mediates 54% of the intermonomer contact surface area in rat arginase I,^[@ref49]^ although mutagenesis studies suggest that mutations in the C-terminus destabilize but do not necessarily prevent the trimerization of rat arginase I or human arginase I.^[@ref50]−[@ref52]^ The unusually long C-terminal tail of SmARG is similarly responsible for the majority of subunit--subunit interactions; the 13-residue extension alone contributes ∼3900 Å^2^ of total buried surface area (36% of the total buried surface area) to trimer assembly.

![(a) Structure of the SmARG homotrimer. α-Helices are colored salmon, β-strands blue, and Mn^2+^ ions purple. The elongated S-shaped C-terminus is colored magenta, and the disordered K111--S119 loop appears as a yellow dotted line. (b) Simulated annealing omit map contoured at 4.0σ of the metal-bound solvent molecules in unliganded SmARG. Atoms are color-coded as follows: white for C, blue for N, red for O, purple spheres for Mn^2+^ ions, and red spheres for solvent molecules. Metal coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively. (c) Superposition of unliganded SmARG (color-coded as in panel b, with black residue labels) and human arginase I (PDB entry 2ZAV; yellow for C, blue for N, red for O, pink spheres for Mn^2+^ ions, and yellow spheres for solvent molecules with red residue labels).](bi-2014-004519_0002){#fig3}

The structure of the binuclear manganese cluster (Figure [3](#fig3){ref-type="fig"}b) is essentially identical to that observed in unliganded arginases from other species, such as human arginase I (Figure [3](#fig3){ref-type="fig"}c). Each Mn^2+^ ion is coordinated in octahedral or distorted octahedral fashion by two nonprotein ligands and conserved metal binding residues. The metal-bridging nonprotein ligand is expected to be a hydroxide ion in the catalytically active state, and the Mn^2+^~A~-bound nonprotein ligand is interpreted as a water molecule. This is similar to the identification of nonprotein metal ligands in unliganded human arginase I,^[@ref40]^*Bacillus caldovelox* arginase,^[@ref53]^ and *Leishmania mexicana* arginase.^[@ref54]^ Most other inner active site residues are conserved in SmARG, except that T135 in human arginase I is conserved as S165 in SmARG (Figure [3](#fig3){ref-type="fig"}c).

Although Fitzpatrick and colleagues suggest that the SmARG activity is dependent on a disulfide bond formed between C291 and C332 on the basis of homology modeling,^[@ref15]^ no disulfide bond is observed in the crystal structure, even though the Sγ atoms of C291 and C332 are only 3.5 Å apart and no reducing agents were included in crystallization buffers (Figure S2a of the [Supporting Information](#notes-2){ref-type="notes"}). It is clear, however, that SmARG activity is severely attenuated in the presence of reducing reagents such as TCEP (Figure S2b of the [Supporting Information](#notes-2){ref-type="notes"}). Our modeling studies indicate that side chain torsion angle χ~2~ of C291 could be rotated by 54° to allow the formation of a disulfide bond with C332. The geometry of this disulfide linkage would be classified as -RHStaple, which corresponds to the geometry of allosteric disulfide linkages that regulate protein function by triggering reversible changes in protein tertiary structure.^[@ref55]^ Even so, the side chain conformations of C291 and C332 would be unfavorable if this disulfide bond were formed.

To probe the functional importance of a possible disulfide linkage between C291 and C332, we prepared the C291A and C332A mutants of SmARG and measured their steady-state kinetics (Table [2](#tbl2){ref-type="other"}). These mutants are chemically incapable of forming a covalent linkage between residues 291 and 332; notably, however, these mutants exhibit significant residual activity (∼30% based on *k*~cat~). Catalytic efficiencies (*k*~cat~/*K*~M~) are compromised 25-fold for C291A SmARG and only 9-fold for C332A SmARG. Thus, formation of a disulfide linkage between C291 and C332 is not required for catalysis but might be required for maximal catalytic function.

Structures of Complexes of SmARG with Simple Amino Acids {#sec3.4}
--------------------------------------------------------

The overall structure of SmARG in each complex with the amino acid inhibitors [l]{.smallcaps}-ornithine, [l]{.smallcaps}-valine, and [l]{.smallcaps}-lysine is essentially identical to the structure of unliganded SmARG; the rmsds between liganded and unliganded structures are 0.17 Å for 322 Cα atoms in the SmARG--[l]{.smallcaps}-ornithine complex, 0.17 Å for 319 Cα atoms in the SmARG--[l]{.smallcaps}-valine complex, and 0.30 Å for 316 Cα atoms in the SmARG--[l]{.smallcaps}-lysine complex. As is evident in Figure [4](#fig4){ref-type="fig"}, the molecular recognition of the catalytic product [l]{.smallcaps}-ornithine, the product analogue [l]{.smallcaps}-lysine, and the weak inhibitor [l]{.smallcaps}-valine is dominated by three direct and four water-mediated hydrogen bonds that selectively accommodate the α-amino and α-carboxyl groups of an amino acid with [l]{.smallcaps}-stereochemistry. This hydrogen bond network comprises the [l]{.smallcaps}-amino acid recognition motif, as first observed in the rat arginase I--ABH complex.^[@ref56]^

![Simulated annealing omit maps of amino acids bound in the active site of SmARG: (a) [l]{.smallcaps}-ornithine, contoured at 3.0σ; (b) [l]{.smallcaps}-valine, contoured at 3.0σ; and (c) [l]{.smallcaps}-lysine, contoured at 5.5σ. Atoms are color-coded as follows: white (protein) or yellow (inhibitor) for C, blue for N, red for O, green for B, purple spheres for Mn^2+^ ions, and red spheres for solvent molecules. Metal coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively. The α-amino and α-carboxyl groups of each amino acid make an array of direct and water-mediated hydrogen bonds with conserved protein residues D213, E216, N160, S165, S167, N169, and H171. These residues comprise the [l]{.smallcaps}-amino acid recognition motif.](bi-2014-004519_0003){#fig4}

Structures of Complexes of SmARG with *N*-Hydroxyguanidinium Inhibitors {#sec3.5}
-----------------------------------------------------------------------

The overall structure of the SmARG--NOHA complex is essentially identical to that of unliganded SmARG, with an rmsd of 0.23 Å for 316 Cα atoms. The α-amino and α-carboxyl groups of NOHA hydrogen bond with the [l]{.smallcaps}-amino acid recognition motif, and the Nη-OH group interacts with the binuclear manganese cluster (Figure [5](#fig5){ref-type="fig"}a). Intriguingly, however, the electron density map indicates that the *N*-hydroxyguanidinium group binds with two alternative conformations. In the major conformation (refined with 75% occupancy), the Nη-OH group of NOHA displaces the metal-bridging hydroxide ion and symmetrically bridges the binuclear manganese cluster with an average Mn^2+^···O coordination distance of 1.8 Å, and the Mn^2+^~A~--Mn^2+^~B~ separation increases from 3.1 to 3.3 Å. The η-NH~2~ group of NOHA is oriented toward Mn^2+^~A~ (but does not coordinate) and donates a hydrogen bond to E307. This conformation is similar to that observed in the 2.9 Å resolution crystal structure of the rat arginase I--NOHA complex (PDB entry 1HQF).^[@ref57]^

![(a) Simulated annealing omit map (contoured at 3.0σ) of the inhibitor NOHA that reveals that the hydroxyguanidinium group adopts two alternate conformations. Atoms are color-coded as in Figure [4](#fig4){ref-type="fig"}. Metal coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively. Note that residue D213 adopts two alternate conformations. (b) Simulated annealing omit map (contoured at 3.0σ) of the inhibitor nor-NOHA. Atoms are color-coded as in Figure [4](#fig4){ref-type="fig"}. Metal coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively.](bi-2014-004519_0004){#fig5}

In the minor conformation (refined with 25% occupancy), the Nη-OH group of NOHA displaces the Mn^2+^~A~-bound water molecule with an average Mn^2+^~A~···O coordination distance of 2.0 Å. The metal-bridging hydroxide ion must also be displaced to accommodate NOHA binding in this conformation, so both Mn^2+^~A~ and Mn^2+^~B~ exhibit square bipyramidal coordination geometry. Two hydrogen bonds are observed between SmARG and NOHA in its minor conformation: the Nη-H group of NOHA donates a hydrogen bond to D158, and the η-NH~2~ group donates a hydrogen bond to T276. These interactions are similar to those observed in the 2.04 Å resolution crystal structure of the human arginase I--NOHA complex (PDB entry 3LP7) (Figure S3 of the [Supporting Information](#notes-2){ref-type="notes"}).^[@ref47]^

Finally, the overall structure of SmARG in its complex with nor-NOHA is essentially identical to that of unliganded SmARG, with an rmsd of 0.19 Å for 331 Cα atoms. The amino acid moiety of nor-NOHA is accommodated by the [l]{.smallcaps}-amino acid recognition motif, as observed for NOHA. However, in contrast with the binding of NOHA, the *N*-hydroxyguanidinium group of nor-NOHA binds with just a single conformation in which the Nζ-OH group displaces the metal-bridging hydroxide ion and bridges the binuclear manganese cluster with average Mn~A~^2+^···O and Mn~B~^2+^···O coordination distances of 1.9 and 2.2 Å, respectively (Figure [5](#fig5){ref-type="fig"}b). The ζ-NH group of nor-NOHA donates a hydrogen bond to D158, and the ζ-NH~2~ group is oriented toward Mn^2+^~B~ (but does not coordinate) and donates a hydrogen bond to T276.

Structures of Complexes of SmARG with Classical Boronic Acid Inhibitors {#sec3.6}
-----------------------------------------------------------------------

The crystal structure of the SmARG--ABH complex reveals that no significant conformational changes are triggered upon inhibitor binding, and the rmsd is 0.15 Å for 318 Cα atoms in comparison with the unliganded enzyme. The simulated annealing omit map in Figure [6](#fig6){ref-type="fig"} reveals that the boronic acid group of ABH undergoes nucleophilic attack, presumably by the metal-bridging hydroxide ion of the native enzyme, to form the tetrahedral boronate anion, which mimics the tetrahedral intermediate and its flanking transition states in the arginase reaction.^[@ref30]^ The α-carboxylate group and α-amino group of ABH hydrogen bond with the [l]{.smallcaps}-amino acid recognition motif, as first observed in the crystal structure of the rat arginase I--ABH complex.^[@ref56]^ This structure serves as a starting point for understanding structure--activity relationships for α,α-disubstituted ABH derivatives described below.

![Simulated annealing omit map (contoured at 3.0σ) of boronic acid inhibitor ABH. Atoms are color-coded as in Figure [4](#fig4){ref-type="fig"}. Metal coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively.](bi-2014-004519_0005){#fig6}

The crystal structure of the SmARG--BEC complex, although determined at a lower resolution of 2.7 Å, similarly reveals the binding of the tetrahedral boronate anion and an array of hydrogen bonds with the α-amino acid moiety (Figure S4 of the [Supporting Information](#notes-2){ref-type="notes"}). No significant conformational changes are triggered upon inhibitor binding, and the rmsd is 0.26 Å for 320 Cα atoms in comparison with the unliganded enzyme. Although fewer water molecules are observed in the active site because of the modest resolution, the structure of the SmARG--BEC complex is similar to that first observed in the rat arginase I--BEC complex.^[@ref31]^

Structures of Complexes of SmARG with α,α-Disubstituted Boronic Acid Inhibitors {#sec3.7}
-------------------------------------------------------------------------------

The structure of the SmARG--ABH complex reveals that the Cα-H group of ABH can be substituted with an additional side chain capable of making additional interactions on the protein surface. To demonstrate the proof of concept, we have determined the crystal structures of SmARG complexes with the novel α,α-disubstituted amino acid inhibitors ABH~PE~ and ABH~DP~ (Figure [1](#fig1){ref-type="fig"}b). The overall structures of SmARG complexed with ABH~PE~ and ABH~DP~ are essentially identical to the structure of unliganded SmARG, with rmsds of 0.19 Å for 332 Cα atoms and 0.17 Å for 330 Cα atoms, respectively. Although racemic ABH~DP~ was used in the crystallization experiment with SmARG, the electron density map clearly shows that the stereoisomer corresponding to [l]{.smallcaps}-ABH binds exclusively in the active site. As shown in Figure [7](#fig7){ref-type="fig"}, the boronic acid moiety of each inhibitor undergoes nucleophilic attack by the metal-bridging hydroxide ion to form a tetrahedral boronate anion, as observed in the crystal structure of the parent SmARG--ABH complex (Figure [6](#fig6){ref-type="fig"}). However, in contrast with the SmARG--ABH complex, the additional α-substituents of ABH~PE~ and ABH~DP~ block the binding of water molecule W4; this water molecule ordinarily mediates a hydrogen bond between the inhibitor α-amino group and D213 (Figure [7](#fig7){ref-type="fig"}c). Therefore, the [l]{.smallcaps}-amino acid recognition motif in the active site of SmARG is slightly compromised by the binding of α,α-disubstituted amino acid inhibitors. Regardless, the additional α-substituents of both ABH~PE~ and ABH~DP~ make additional interactions in the active site of SmARG, which presumably accounts for the affinity of these inhibitors being higher than that of ABH.

![Simulated annealing omit maps of α,α-disubstituted amino acid inhibitors: (a) ABH~PE~, contoured at 5.0σ, and (b) ABH~DP~, contoured at 3.0σ. Atoms are color-coded as in Figure [4](#fig4){ref-type="fig"} (dark green for Cl). Metal coordination and hydrogen bond interactions are represented by red and green dashed lines, respectively. Note that residue E58 from an adjacent monomer of the homotrimer adopts two alternate conformations (highlighted in cyan). (c) Superposition of the SmARG--ABH complex (white for C and Mn^2+^), the SmARG--ABH~PE~ complex (salmon for C and Mn^2+^), and the SmARG--ABH~DP~ complex (yellow for C and Mn^2+^).](bi-2014-004519_0006){#fig7}

In each enzyme--inhibitor complex, the piperidine ring exclusively adopts a chair conformation and its protonated tertiary amino group donates a hydrogen bond to D213 (purple dashed lines in panels a and b of Figure [7](#fig7){ref-type="fig"}; average N···O separations of 2.7 Å in the SmARG--ABH~PE~ complex and 2.9 Å in the SmARG--ABH~DP~ complex). Additionally, the dichlorobenzyl group of ABH~DP~ interacts with E58 from an adjacent monomer (panels b and c of Figure [7](#fig7){ref-type="fig"}). Incomplete electron density for the dichlorobenzyl group of ABH~DP~ and a higher average temperature factor (∼55 Å^2^) compared with that of the piperidine ring (∼30 Å^2^) suggest increased flexibility.

Structural comparison of the SmARG--ABH~PE~ complex with the 1.30 Å resolution crystal structure of the human arginase I--ABH~PE~ complex (PDB entry 4HWW)^[@ref34]^ reveals striking differences in the conformation of the piperidine α-substituent of ABH~PE~, even though the parent ABH scaffold retains the same conformation in both structures (Figure [8](#fig8){ref-type="fig"}a). Van Zandt and colleagues note that the piperidine ring of ABH~PE~ adopts two alternate conformations in the human arginase I--ABH~PE~ complex: distorted boat (66%) and chair (33%).^[@ref34]^ With the piperidine ring of ABH~PE~ shifted farther from D183 in the human arginase I--ABH~PE~ complex (D183 of human arginase I corresponds to D213 of SmARG), it makes water-mediated hydrogen bonds with D183 and D181 through water molecules W1 and W4, instead of making a direct hydrogen bond as observed in the SmARG--ABH~PE~ complex. More importantly, because of the conservation of water molecule W4, the [l]{.smallcaps}-amino acid recognition motif is intact in the human arginase I--ABH~PE~ complex.

![(a) Superposition of the SmARG--ABH~PE~ complex \[white (protein) or yellow (inhibitor) for C\] with the human arginase I--ABH~PE~ complex (cyan for C; PDB entry 4HWW). (b) Superposition of the SmARG--ABH~DP~ complex \[white (protein) or yellow (inhibitor) for C\] with the human arginase II--ABH~DP1~ complex (cyan for C; PDB entry 4IXV). Selected hydrogen bonds are shown as purple dashed lines (SmARG) or black dashed lines (human arginases). Solvent molecules are shown as small red spheres; Mn^2+^ ions are shown as purple and orange spheres in SmARG and human arginases, respectively. Black residue labels correspond to SmARG, and red labels correspond to the human arginases.](bi-2014-004519_0007){#fig8}

Structural differences in the binding of an α,α-disubstituted amino acid are also revealed in the comparison of the SmARG--ABH~DP~ complex with the complex between human arginase II and (*R*)-2-amino-6-borono-2-\[1-(4-chlorobenzyl)piperidin-4-yl\]hexanoate (ABH~DP1~, which differs from ABH~DP~ by one chlorine atom on the pendant aromatic ring; PDB entry 4IXV)^[@ref35]^ (Figure [8](#fig8){ref-type="fig"}b). Here, too, the parent ABH structures adopt similar conformations; however, significant conformational differences are observed for the additional α-substituents of ABH~DP~ and ABH~DP1~. The piperidine ring of ABH~DP1~ in the human arginase II--ABH~DP1~ complex adopts a distorted boat conformation, with the piperidine amino group forming a water-mediated hydrogen bond with S155 (equivalent to T136 in human arginases I and II), instead of hydrogen bonding with D213, as observed in the SmARG--ABH~DP1~ complex. Additionally, the chlorobenzyl ring of ABH~DP1~ does not interact with the protein.

Active site comparisons reveal that A166 (equivalent to T136 in human arginase I and S155 in human arginase II) is another nonconserved residue in SmARG (besides S165) that can interact with α,α-disubstituted amino acid inhibitors (Figure [8](#fig8){ref-type="fig"}). Interestingly, the corresponding residue is similarly nonpolar in two other parasitic arginases: P228 in *Plasmodium falciparum* arginase^[@ref58]^ and V149 in *L. mexicana* arginase.^[@ref54]^ Differences in polarity and size at this position between parasitic arginases and human arginases may be a contributing factor to the alternative binding modes of α,α-disubstituted amino acid inhibitors.

Coculture of Schistosomula with ABH, NOHA, and nor-NOHA {#sec3.8}
-------------------------------------------------------

The helminth fluorescence bioassay was utilized to assess the effect of SmARG inhibitors on schistosomula viability during continuous *in vitro* cocultivation. Despite the ability of these inhibitors to effectively bind to SmARG, no significant difference in parasite viability or morphology was observed during treatment with 100 μM ABH, NOHA, or nor-NOHA for 24 h (Figure S5 of the [Supporting Information](#notes-2){ref-type="notes"}) or 72 h (data not shown). If the uptake of amino acid inhibitors is facile, this result suggests that any effect of SmARG inhibitors on parasite viability would require the presence of the human host.

Discussion {#sec4}
==========

Biological Insight into SmARG as a Drug Target for Schistosomiasis {#sec4.1}
------------------------------------------------------------------

Using a 37632-element long-oligonucleotide DNA microarray, new *S. mansoni* anthelmintic drug targets were revealed through parasite life cyle transcriptomic profiling.^[@ref45]^ Here, we show that one putative drug target, SmARG,^[@ref15]^ is maximally expressed in all life stages that interact with the definitive mammalian host but minimally expressed in life stages that interact with the intermediate snail host (Figure [2](#fig2){ref-type="fig"}). These data confirm previously published semiquantitative reverse transcription PCR data and indicate that the upregulation of SmARG is specific to human infection by *S. mansoni*. Curiously, however, SmARG is not secreted by cercariae or schistosomula,^[@ref15]^ so the influence of *S. mansoni* infection on [l]{.smallcaps}-arginine concentrations in infected human tissues presumably arises from the facile transport of [l]{.smallcaps}-arginine into the parasite. The resultant depletion of host [l]{.smallcaps}-arginine pools allows immune evasion, because depressed [l]{.smallcaps}-arginine concentrations can result in lower NO concentrations produced by classically activated macrophages with known anti-schistosomula function.^[@ref59]^

In principle, then, the inhibition of SmARG might possibly render the parasite more susceptible to host immunity during infection. Consistent with this hypothesis, the classical arginase inhibitors ABH, NOHA, and nor-NOHA do not affect parasite viability in the absence of the host (Figure S5 of the [Supporting Information](#notes-2){ref-type="notes"}). The host immune response *in vivo* is presumably required for the maximal anthelmintic effect of an arginase inhibitor, as is the case for praziquantel.^[@ref60]^

Inhibitor Design Strategy for SmARG {#sec4.2}
-----------------------------------

Although the affinities of the classical arginase inhibitors ABH, NOHA, and nor-NOHA are in the low micromolar range (Table [2](#tbl2){ref-type="other"}), it is somewhat surprising that these affinities fall short of the nanomolar binding affinities reported for complexes with human arginase I.^[@ref16],[@ref47]^ The structural basis of the weaker affinity is not clear on the basis of analysis of the crystal structures, because each inhibitor makes essentially identical metal coordination and hydrogen bond interactions in the active site of SmARG compared with the active sites of mammalian enzymes. It is clear, however, that the best inhibitors of arginase from any species will bear side chains capable of metal ion coordination. This accounts for the generally weaker binding affinity of simple amino acids such as [l]{.smallcaps}-valine, [l]{.smallcaps}-ornithine, and [l]{.smallcaps}-lysine, which do not interact directly with the active site Mn^2+^ ions (Figure [4](#fig4){ref-type="fig"}). Parenthetically, we note that this feature facilitates release of the [l]{.smallcaps}-ornithine product during catalysis.

The crystal structures of complexes of SmARG with ABH and nor-NOHA reveal that the tetrahedral boronate anion and the *N*-hydroxyguanidinium moiety serve as ideal functional groups for metal ion coordination and active site hydrogen bond interactions (Figures [5](#fig5){ref-type="fig"}b and [6](#fig6){ref-type="fig"}). The α-carboxylate and α-amino group of each inhibitor also make an array of hydrogen bond interactions with the [l]{.smallcaps}-amino acid recognition motif, and these hydrogen bonds similarly make an important contribution to enzyme--inhibitor affinity.^[@ref61]^ Thus, in the quest to improve SmARG--inhibitor affinity and selectivity, these conserved features of enzyme--inhibitor recognition cannot be perturbed.

Inspection of the crystal structure of the SmARG--ABH complex (Figure [6](#fig6){ref-type="fig"}) revealed that the [l]{.smallcaps}-amino acid moiety is oriented such that the Cα-H group could be substituted with a longer side chain to generate an α,α-disubstituted amino acid capable of maintaining active site interactions with its "[l]{.smallcaps}-side chain" while engaging in new interactions on the protein surface with its "[d]{.smallcaps}-side chain". The binding of ABH~PE~ and ABH~DP~ (Figure [7](#fig7){ref-type="fig"}) with 2- and 5-fold higher affinity, respectively (Figure S1 of the [Supporting Information](#notes-2){ref-type="notes"}), demonstrates the success of this strategy. Furthermore, structural comparisons of the region that accommodates the [d]{.smallcaps}-side chains of ABH~PE~ and ABH~DP~ indicate that this region, designated the "[d]{.smallcaps}-cleft" or "T136 region",^[@ref62]^ differs between SmARG and human arginase I. Specifically, the [d]{.smallcaps}-cleft of SmARG is much more nonpolar and perhaps would better accommodate hydrophobic [d]{.smallcaps}-side chains even longer than that of ABH~DP~. Therefore, α,α-disubstituted amino acid inhibitors based on the ABH or nor-NOHA scaffoldings with [d]{.smallcaps}-side chains even more extensive than that of ABH~DP~ could be designed to further enhance binding affinity as well as selectivity against SmARG. Future studies in this regard will be reported in due course.

Isothermal titration calorimetry data for SmARG--inhibitor complexes, simulated annealing omit map of C291 and C332 in unliganded SmARG, superposition of the SmARG--NOHA complex with the human arginase I--NOHA complex, simulated annealing omit map of the SmARG--BEC complex, and helminth fluorescence bioassay data. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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ABH

:   2(*S*)-amino-6-boronohexanoic acid

ABH~DP~

:   (*R*)-2-amino-6-borono-2-\[1-(3,4-dichlorobenzyl)piperidin-4-yl\]hexanoic acid

ABH~DP1~

:   (*R*)-2-amino-6-borono-2-\[1-(4-chlorobenzyl)piperidin-4-yl\]hexanoate

ABH~PE~

:   (*R*)-2-amino-6-borono-2-\[2-(piperidin-1-yl)ethyl\]hexanoic acid

BEC

:   *S*-(2-boronoethyl)-[l]{.smallcaps}-cysteine

EPPS

:   4-(2-hydroxyethyl)piperazine-1-propanesulfonic acid

ITC

:   isothermal titration calorimetry

NOHA

:   *N*-hydroxy-[l]{.smallcaps}-arginine

nor-NOHA

:   nor-*N*-hydroxy-[l]{.smallcaps}-arginine

PDB

:   Protein Data Bank

rmsd

:   root-mean-square deviation

TCEP

:   tris(2-carboxyethyl)phosphine hydrochloride.
